Anti-PD-L1 monotherapy (compared with anti-PD-1 monotherapy, OR, 0.48; 95% CI, 0.35-0.67; P < .01) and sequential therapy of anti-PD-1 and anti-PD-L (compared with anti-PD-1 monotherapy, OR, 0.36; 95% CI, 0.17-0.78; P < .01) were associated with a decreased risk of adrenal insufficiency. This evidence concerns the gene PDCD1 and Adrenal insufficiency.